The risk of cancer in people with diabetes and chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 27, Issue 8, 2012, Pages 3337-3344

  Wong, Germaine ^a,b,c   Zoungas, Sophia ^d   Lo, Serigne ^d   Chalmers, John ^d   Cass, Alan ^d   Neal, Bruce ^e   Woodward, Mark ^d   Perkovic, Vlado ^d   Glasziou, Paul ^f   Williams, Bryan ^g   Howard, Kirsten ^b   Chapman, Jeremy R ^c   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f BOND UNIVERSITY   (Australia)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

cancer; CKD; cumulative incidence; diabetes

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CHRONIC KIDNEY DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SKIN CANCER; URINARY TRACT CANCER;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84864629526     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs022     Document Type: Article

References (48)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
2. Kiberd B. The chronic kidney disease epidemic: stepping back and looking forward. J Am Soc Nephrol 2006; 17: 2967-2973.
3. Mathew T. Addressing the epidemic of chronic kidney disease in Australia. Nephrology 2004; 9 (Suppl 12): S109-S112.
4. LeRoith D, Novosyadlyy R, Gallagher EJ et al. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 2008; 116 (Suppl 6): S4-S6.
5. Inoue M, Iwasaki M, Otani T et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871-1877.
6. Friberg E, Orsini N, Mantzoros CS et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007; 50: 1365-1374.
7. Huxley R, Ansary-Moghaddam A, Berrington de González A et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083.
8. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-1687.
9. Larsson SC, Orsini N, Brismar K et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-2823.
10. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-862.
11. Lam EK, Batty GD, Huxley RR et al. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol 2011; 22: 730-738.
12. Stefansdottir G, Zoungas S, Chalmers J et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011; 54: 1608-1614.
13. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831.
14. Wong G, Hayen A, Chapman JR et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009; 20: 1341-1350.
15. Jorgensen L, Heuch I, Jenssen T et al. Association of albuminuria and cancer incidence. J Am Soc Nephrol 1919; 5: 992-998.
16. ADVANCE Collaborative Group. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120.
17. Patel A, MacMahon S et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
18. Huncharek M, Haddock KS, Reid R et al. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 2010; 100: 693-701.
19. Tanaka K, Tsuji I, Wakai K et al. Cigarette smoking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among Japanese. Jpn J Clin Oncol 2006; 36: 445-456.
20. Wakai K, Inoue M, Mizoue T et al. Tobacco smoking and lung cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol 2006; 36: 309-324.
21. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 449: 496-509.
22. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010; 55: 622-627.
23. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
24. Dube DH, Bertozzi CR. Glycans in cancer and inflammation- potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 6: 477-488.
25. Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer 2010; 127: 768-779.
26. Mantovani A, Allavena P, Sica A et al. Cancer-related inflammation. Nature 2008; 454: 436-444.
27. Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets 2009; 8: 369-382.
28. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006; 97: 3A-11A.
29. Sonnett TE, Levien TL, Gates BJ et al. Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies. Ann Pharmacother 2010; 44: 701-711.
30. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010; 16: 133-144.
31. Hsu IR, Kim SP, Kabir M et al. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 2007; 86: s867-s871.
32. Loh WJ, North BV, Johnston DG et al. Insulin resistance-related biomarker clustering and subclinical inflammation as predictors of cancer mortality during 21.5 years of follow-up. Cancer Causes Control 2010; 21: 709-718.
33. Trevisan M, Liu J, Muti P et al. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001; 10: 937-941.
34. Bruning PF, Bonfrer JM, van Noord PA et al. Insulin resistance and breast-cancer risk. Int J Cancer 1992; 52: 511-516.
35. Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinaemia- diabetes-cancer link for preventive efforts. Eur J Cancer Prev 1998; 7: 89-107.
36. Goodwin PJ, Ennis M, Bahl M et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2009; 114: 517-525.
37. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-625.
38. Ramos-Nino M, MacLean C, Littenberg B. Association of angiotensin- converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information system. BMC Endocr Disord 2008; 8: 17..
39. Ehrlich SF, Quesenberry CP, Jr, Van Den Eeden SK et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33: 55-60.
40. Hall GC, Roberts CM, Boulis M et al. Diabetes and the risk of lung cancer. Diabetes Care 2005; 28: 590-594.
41. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-2062.
42. Ganz PA, Habel LA, Weltzien EK et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011; 129: 549-556.
43. Yoon C, Yang HS, Jeon I et al. Use of angiotensin-convertingenzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ 2011; 183: E1073-E1084.
44. Sipahi I, Chou J, Mishra P et al. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol 2011; 108: 294-301.
45. Webster AC, Craig JC, Simpson JM et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007; 7: 2140-2151.
46. Adami J, Gabel H, Lindelof B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-1227.
47. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000; 355: 1886-1887.
48. Kauffman HM. Malignancies in organ transplant recipients. J Surg Oncol 2006; 94: 431-433